1966 related articles for article (PubMed ID: 26051365)
1. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
[TBL] [Abstract][Full Text] [Related]
2. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K;
Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.
Bissonnette R; Iversen L; Sofen H; Griffiths CE; Foley P; Romiti R; Bachinsky M; Rottinghaus ST; Tan H; Proulx J; Valdez H; Gupta P; Mallbris L; Wolk R
Br J Dermatol; 2015; 172(5):1395-406. PubMed ID: 25418186
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
Papp KA; Menter MA; Abe M; Elewski B; Feldman SR; Gottlieb AB; Langley R; Luger T; Thaci D; Buonanno M; Gupta P; Proulx J; Lan S; Wolk R;
Br J Dermatol; 2015 Oct; 173(4):949-61. PubMed ID: 26149717
[TBL] [Abstract][Full Text] [Related]
5. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Burmester GR; Blanco R; Charles-Schoeman C; Wollenhaupt J; Zerbini C; Benda B; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Soma K; Bradley J; Mebus C;
Lancet; 2013 Feb; 381(9865):451-60. PubMed ID: 23294500
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study.
Valenzuela F; Paul C; Mallbris L; Tan H; Papacharalambous J; Valdez H; Mamolo C
J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):1753-1759. PubMed ID: 27271195
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.
Papp KA; Menter A; Strober B; Langley RG; Buonanno M; Wolk R; Gupta P; Krishnaswami S; Tan H; Harness JA
Br J Dermatol; 2012 Sep; 167(3):668-77. PubMed ID: 22924949
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
Mamolo C; Harness J; Tan H; Menter A
J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):192-203. PubMed ID: 23294276
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.
Menter A; Papp KA; Tan H; Tyring S; Wolk R; Buonanno M
J Drugs Dermatol; 2014 Mar; 13(3):252-6. PubMed ID: 24595567
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.
Abe M; Nishigori C; Torii H; Ihn H; Ito K; Nagaoka M; Isogawa N; Kawaguchi I; Tomochika Y; Kobayashi M; Tallman AM; Papp KA
J Dermatol; 2017 Nov; 44(11):1228-1237. PubMed ID: 28714180
[TBL] [Abstract][Full Text] [Related]
12. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
[TBL] [Abstract][Full Text] [Related]
13. Etanercept treatment for children and adolescents with plaque psoriasis.
Paller AS; Siegfried EC; Langley RG; Gottlieb AB; Pariser D; Landells I; Hebert AA; Eichenfield LF; Patel V; Creamer K; Jahreis A;
N Engl J Med; 2008 Jan; 358(3):241-51. PubMed ID: 18199863
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
[TBL] [Abstract][Full Text] [Related]
15. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
Papp KA; Bissonnette R; Gooderham M; Feldman SR; Iversen L; Soung J; Draelos Z; Mamolo C; Purohit V; Wang C; Ports WC
BMC Dermatol; 2016 Oct; 16(1):15. PubMed ID: 27716172
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study.
Zhang J; Tsai TF; Lee MG; Zheng M; Wang G; Jin H; Gu J; Li R; Liu Q; Chen J; Tu C; Qi C; Zhu H; Ports WC; Crook T
J Dermatol Sci; 2017 Oct; 88(1):36-45. PubMed ID: 28558978
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
Papp K; Cather JC; Rosoph L; Sofen H; Langley RG; Matheson RT; Hu C; Day RM
Lancet; 2012 Aug; 380(9843):738-46. PubMed ID: 22748702
[TBL] [Abstract][Full Text] [Related]
18. Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis.
Fitz L; Zhang W; Soderstrom C; Fraser S; Lee J; Quazi A; Wolk R; Mebus CA; Valdez H; Berstein G
Clin Exp Dermatol; 2018 Oct; 43(7):790-797. PubMed ID: 29748971
[TBL] [Abstract][Full Text] [Related]
19. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
[TBL] [Abstract][Full Text] [Related]
20. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
